Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.

Yoon, Dok Hyun

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. [electronic resource] - Investigational new drugs Apr 2012 - 819-27 p. digital

Publication Type: Journal Article

1573-0646

10.1007/s10637-010-9593-1 doi


Adult
Aged
Antineoplastic Agents--therapeutic use
Asian People--genetics
Benzamides
Chi-Square Distribution
DNA Mutational Analysis
Disease Progression
Disease-Free Survival
Exons
Female
Gastrointestinal Stromal Tumors--drug therapy
Genetic Predisposition to Disease
Humans
Imatinib Mesylate
Indoles--adverse effects
Kaplan-Meier Estimate
Male
Middle Aged
Molecular Targeted Therapy
Multivariate Analysis
Mutation
Phenotype
Piperazines--adverse effects
Protein Kinase Inhibitors--adverse effects
Proto-Oncogene Proteins c-kit--antagonists & inhibitors
Pyrimidines--adverse effects
Pyrroles--adverse effects
Receptor, Platelet-Derived Growth Factor alpha--antagonists & inhibitors
Republic of Korea--epidemiology
Retrospective Studies
Risk Assessment
Risk Factors
Sunitinib
Time Factors
Treatment Failure